Greenwich LifeSciences Inc.

GLSI | NASDAQ

Price Alert Chart Builder DCF Calculator

$18.50

-$0.49 (-2.58%)

Sep 21, 2026, 11:54 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-2.58%

(1D)

Rating

Updated: Sep 5, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $271.55M

1D Range

18.19 19.24

52W Range

7.78 34.10

Valuation (TTM)

PE -12.33

PB 89.43

EV/EBITDA -12.45

Valuation (NTM)

Forward PE N/A

Forward PEG 0.79

Price Target $50

Cash Flow

FCF Yield -4.5%

SBC Adj. FCF Yield -6.1%

SBC Impact -36.6%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y -30.5% | -29.7%

FCF 3Y | 5Y -30.8% | -20.1%

Returns

ROA -244.3%

ROE -793.8%

ROIC -701.5%

Financial Health

Net Cash

$8.88M

Current Ratio 1.54

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer...

Sector Healthcare

Industry Biotechnology

Employees 13

IPO Date Sep 24, 2020

Website greenwichlifesciences.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$50

Upside

+170.27%

Buy (1)

Hold (0)

Sell (0)

Analyst Details ➞